This trial is evaluating whether Cyclophosphamide will improve 2 primary outcomes, 8 secondary outcomes, and 1 other outcome in patients with Relapse. Measurement will happen over the course of Up to 28 days from infusion.
This trial requires 24 total participants across 1 different treatment group
This trial involves a single treatment. Cyclophosphamide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"A diagnosis of [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia) or chronic myeloid leukemia is a serious health issue that can cause serious problems when present in the early part of the disease. The most frequent types of chronic lymphocytic leukemia or chronic myeloid leukemia are B cell chronic lymphocytic leukemia or chronic myeloid leukemia (CLL/CML); CLL/CML." - Anonymous Online Contributor
"The cause of leukemia is not clear, but researchers believe it may be a combination of genetic, environmental, diet, and other influences. In particular, researchers believe that certain environmental exposures, such as exposure to radiation, may increase leukemia risk.\n" - Anonymous Online Contributor
"Because current data suggest that a growing number of people will develop cancer over time, our focus will continue to be on developing a general definition of cancer in this population and developing tools that help clinicians plan care to be optimized." - Anonymous Online Contributor
"Findings from a recent study suggest that a complete remission (CR) can be achieved in some patients with B chronic lymphocytic leukemia (CLL) using an intense consolidation chemotherapy for 6 or longer treatments with the aim of cure." - Anonymous Online Contributor
"There is little evidence of clinical efficacy for any of the treatment modalities analyzed. Most of the trials were single-agent, short-lived therapies (i.e., <3 months) that had disappointing results. Further study is needed to determine if these results generalize to most leukemia patients, and if other treatment modalities would be better alternatives for longer-term, disease-free treatment." - Anonymous Online Contributor
"Signs of leukemia manifest as lightheadedness, feeling unwell, loss of vigor, and a change in appetite. Other signs may include swollen lymph nodes (usually under the collar-bones), weight loss due to anaemia, or low red blood cell count. Many cases of chronic fatigue syndrome (CFS) have a sudden onset of severe, often debilitating symptoms, which sometimes include nausea, aching and weakness, and the symptoms can be severe, and they can lead to a diagnosis of CFS. A diagnosis of Lyme disease requires the presence of erythema migrans rash, fatigue, and/or a positive ELISA test for infection. The latter must be carried out by an experienced laboratory." - Anonymous Online Contributor
"<nowiki>http://www.nhlbi.nih.gov/prog[ra](https://www.withpower.com/clinical-trials/ra)ms/leucoma/[leukemia](https://www.withpower.com/clinical-trials/leukemia).html</nowiki> The average age-group for leukemia patients in 2019 is 15.14 (3,867 patients). The age range of patients diagnosed with Lymphocytic Chronic B-Cell leukemia was 12.97 to 21.23 (2,849 patients)<nowiki>.</nowiki> The mean age of men diagnosed with lymphocytic chronic B-cell leukemia was 16.7 and women diagnosed with lymphocytic chronic B-cell leukemia was 17.47." - Anonymous Online Contributor
"Common side effects are reported during treatment with cyclophosphamide with the frequency of occurrence below 20% (NCT00367961). Moreover, most frequently reported side effects are infusion-related symptoms which are reversible after infusion discontinuation. Nevertheless, a complete blood count should be done to monitor the blood cell counts at baseline and during treatment with cyclophosphamide." - Anonymous Online Contributor
"Patients receiving CSA have similar overall health-related quality of life when compared with those receiving CC for a year, and this result was not adversely related to the higher incidence of infections and lower survival observed in this cohort (P = 0.5989). Findings from a recent study indicates that CSA has no clinically significant impact on patient quality of life in general and is not recommended for treatment of [chronic lymphocytic leukemia](https://www.withpower.com/clinical-trials/chronic-lymphocytic-leukemia), chronic neutropenic leukemia, or CLL with concomitant myelosuppression." - Anonymous Online Contributor
"The use of A + cyclophosphamide-A + TSH was frequently reported; however, data to support the efficacy of this approach was typically limited. [Power (http://www.withpower.com/clinical-trials/cancer/cyclophosphamide)) Cyclophosphamide is typically used in combination with other treatments, but there was no evidence available to support the use of it alone. Please see Power to find evidence (references below) related to therapy. Cytostatics such as cyclophosphamide are typically used in patients who (a) have undergone hematopoietic stem cell transplantation and (b) develop progressive disease that has failed other treatment strategies." - Anonymous Online Contributor
"The survival rate for leukemia, lymphocytic, chronic, b-cell at 10 to 11 years of age with TPAB is 20%. The 5-year survival rate is 8%; and the overall survivals are 13%. Thus, leukemia, lymphocytic, chronic, b-cell is a serious disease in children with TPAB." - Anonymous Online Contributor
"A combination of cyclophosphamide and low-dose doxorubicin, an antimicrotubule agent in combination with calcineurin inhibitors, is associated with high rates of complete remission. Cyclophosphamide is now more widely used after the development of anthracycline-containing regimens and is being used to treat other neoplasms as well as acute leukemia. In addition, this combination was found to be very well tolerated in a prospective randomized trial of patients with chronic lymphocytic leukemia. This combination is recommended for further investigation to ascertain its usefulness as an induction regimen and for patients unfit for standard induction regimens." - Anonymous Online Contributor